Report on the risk assessment of 2C-I, 2C-T-2 and 2C-T-7 in the framework of the joint action on new synthetic drugs
The risk-assessment reports on the synthetic drugs 2C-I; 2C-T-2 and 2C-T-7 were submitted by the EMCDDA to the European Council and Commission on 4 April 2003. The reports were drawn up at a meeting in Lisbon from 31 March to 1 April under the auspices of an enlarged EMCDDA Scientific Committee. The drugs were singled out by the Council of the EU for risk assessment on 12 December 2002 under the 1997 Joint action on new synthetic drugs. The reports conclude that, due to their structural features, the drugs are potent hallucinogens/stimulants, similar to substances already classified under Schedules I and II of the 1971 UN Convention on Psychotropic Substances. They also note that the substances have no current medical or industrial use. The reports recommend that, due to a potential serious health risk, the drugs should be controlled substances, although some experts consider that insufficient scientific evidence exists to support such a decision. Experts agreed however that whatever the control measures chosen, they should contribute to collecting and disseminating accurate information on the substances to users, and to relevant professionals for preventive and harm-reduction purposes.
Download as PDF
Table of contents
- Reports on the risk assessment of 2C-I, 2C-T-2 and 2C-T-7 in the framework of the joint action on new synthetic drugs
- Europol–EMCDDA progress report on 2C-I, 2C-T-2 and 2C-T-7
- Review of the pharmacotoxicological data on 2C-I, 2C-T-2 and 2C-T-7
- Sociological and criminological evidence and public health risks of 2C-I, 2C-T-2 and 2C-T-7